On September 13, 2026, the Wall Street Journal reported that Pfizer Inc. (NYSE:PFE) is enforcing a Belgian court judgment against Poland and Romania over unpaid COVID-19 vaccine orders by targeting an unusual source of leverage: air traffic control fees.
Eurocontrol, the intergovernmental body that coordinates European air traffic management, has frozen transfers of airline route charges owed to Poland’s and Romania’s air navigation agencies. It happened after Pfizer moved to enforce an April court ruling requiring the two countries to pay a combined roughly $2.1 billion for vaccine doses they declined to accept under a 2021 European Union contract.
Don’t Miss: Novo Nordisk (NVO) and Eli Lilly (LLY)’s Weight-Loss Drugs Still Work at Smaller Doses, Study Finds
Bull Case
Pfizer Inc. (NYSE:PFE) enters the dispute from a strong legal position after winning an enforceable Belgian court ruling. In April, the Brussels court rejected Poland’s and Romania’s arguments for abandoning their pandemic-era purchase commitments. The court ordered them to accept and pay for €1.9 billion, or about $2.2 billion, of Pfizer-BioNTech vaccines. Poland accounts for €1.3 billion of that amount and Romania for €600 million. It gives Pfizer a court-backed claim rather than an unresolved contractual demand.
Pfizer’s enforcement effort could protect significant contractual value that Poland and Romania stopped honoring after COVID demand collapsed. Eurocontrol has already withheld air-navigation fees from Poland and imposed a precautionary seizure tied to Romania. It shows that Pfizer has moved beyond simply winning a judgment and has begun using legal mechanisms to pursue collection. Romania’s health minister also said the ruling remains enforceable during an appeal, which strengthens Pfizer’s position even as litigation continues.
Pfizer’s overall business reduces the importance of this dispute to its long-term investment case. Second-quarter results beat expectations as Eliquis sales rose 21% to $2.43 billion. Padcev sales climbed 23% to $667 million, helping offset declining COVID-related revenue. Pfizer also raised the lower end of its 2026 revenue outlook and now expects $60.5 billion to $62.5 billion in sales. So any eventual recovery from the vaccine contracts would supplement a business that is already shifting toward non-COVID products.
Look Into: AstraZeneca (AZN) Wins FDA Approval for its Breast Cancer Pill After Regulators Voiced Doubts
Bear Case
Pfizer Inc. (NYSE:PFE)’s decision to target air-navigation fees creates significant reputational risk even though the company has a court judgment behind it. Poland’s air traffic agency says airline fees provide more than 80% of its income. Polish and Romanian aviation authorities have warned that freezing those funds could threaten essential operations and air safety. Pfizer may have a legal right to pursue payment. However, investors still need to consider the public backlash that can follow aggressive enforcement against infrastructure agencies.
Poland and Romania are challenging the rulings, so Pfizer still faces legal uncertainty over the ultimate outcome. Poland has said it will pursue all available legal remedies. Romania has also challenged the enforcement measures. The judgments currently allow Pfizer to seek payment, but successful appeals or changes to the enforcement process could delay collection, return seized funds or prolong the dispute for years.
The dispute keeps Pfizer tied to politically sensitive COVID-era contracts just as management works to move the investment story toward newer products and pipeline growth. Pfizer now relies on drugs such as Eliquis, Padcev, and acquired assets to offset declining COVID revenue and upcoming patent expirations. A prolonged public fight with European governments over unwanted vaccine doses could distract from that transition and strain relationships with public-sector customers and policymakers even if Pfizer ultimately prevails in court.
Hedge Fund Sentiment
Pfizer Inc. (NYSE:PFE)’s hedge fund count held steady at 83 funds in both the second and first quarters, though position value fell to $4.71 billion from $6.15 billion, according to Insider Monkey’s database. Bristol Myers Squibb, a fellow large pharmaceutical company navigating its own portfolio transitions, saw holders decline to 74 from 83, with position value also falling to $4.79 billion from $5.97 billion.
Conclusion
Pfizer Inc. (NYSE:PFE) has a strong legal foundation for pursuing Poland and Romania after a Belgian court ordered the two governments to honor roughly $2.2 billion of vaccine commitments. The company has already begun using established enforcement mechanisms to seek payment. Its improving non-COVID portfolio also means the dispute does not define Pfizer’s broader growth strategy.
However, targeting air-navigation fees creates reputational and political risk. Ongoing appeals leave uncertainty around the timing and final amount Pfizer may ultimately collect. Investors should look at the dispute as a potentially valuable legal recovery rather than a core earnings driver while watching whether Pfizer can enforce its contracts without damaging important government relationships in Europe.
Read Next: AstraZeneca (AZN)’s Lung Drug Delivers the Good News its Pipeline Needed and Revolution Medicines (RVMD) Gets its First Approved Drug, and the Market Shrugs
Hedge Fund Resource Center